Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DNAOTCMKTS:IPHYFNASDAQ:RLAYNASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNAGinkgo Bioworks$7.92+3.3%$7.17$5.00▼$34.78$459.75M1.291.46 million shs820,831 shsIPHYFInnate Pharma$1.45$2.01$1.45▼$1.76$121.55M0.551,445 shsN/ARLAYRelay Therapeutics$2.81+0.7%$2.87$1.78▼$10.72$481.76M1.652.07 million shs1.28 million shsTSHATaysha Gene Therapies$2.70+5.5%$1.72$1.05▼$4.32$553.65M0.92.85 million shs4.81 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNAGinkgo Bioworks-1.28%-2.35%-7.15%-47.78%-78.43%IPHYFInnate Pharma0.00%0.00%0.00%-50.00%-34.09%RLAYRelay Therapeutics+0.72%-7.77%+1.09%-30.25%-58.94%TSHATaysha Gene Therapies+8.02%+21.90%+101.57%+57.06%-17.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNAGinkgo Bioworks1.0329 of 5 stars0.83.00.00.02.42.51.3IPHYFInnate PharmaN/AN/AN/AN/AN/AN/AN/AN/ARLAYRelay Therapeutics3.3612 of 5 stars4.41.00.00.03.92.50.6TSHATaysha Gene Therapies2.8117 of 5 stars4.50.00.00.02.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNAGinkgo Bioworks 1.67Reduce$5.77-27.21% DownsideIPHYFInnate Pharma 0.00N/AN/AN/ARLAYRelay Therapeutics 2.83Moderate Buy$17.67528.71% UpsideTSHATaysha Gene Therapies 3.00Buy$6.57143.39% UpsideCurrent Analyst Ratings BreakdownLatest IPHYF, TSHA, RLAY, and DNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025TSHATaysha Gene TherapiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.005/7/2025RLAYRelay TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $10.004/28/2025TSHATaysha Gene TherapiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.004/28/2025TSHATaysha Gene TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.004/17/2025RLAYRelay TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$4.004/10/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/7/2025RLAYRelay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/27/2025RLAYRelay TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.002/27/2025RLAYRelay TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$27.00 ➝ $23.002/27/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.002/26/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNAGinkgo Bioworks$237.42M1.94N/AN/A$21.93 per share0.36IPHYFInnate Pharma$66.71M1.82N/AN/A$0.70 per share2.07RLAYRelay Therapeutics$7.68M62.74N/AN/A$5.90 per share0.48TSHATaysha Gene Therapies$8.33M66.44N/AN/A$0.40 per share6.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNAGinkgo Bioworks-$892.87M-$9.16N/AN/AN/A-298.78%-58.54%-34.24%N/AIPHYFInnate Pharma-$8.19MN/A0.00∞N/AN/AN/AN/AN/ARLAYRelay Therapeutics-$341.97M-$2.23N/AN/AN/AN/A-45.75%-40.75%N/ATSHATaysha Gene Therapies-$111.57M-$0.364.29N/AN/A-229.67%-106.36%-49.16%N/ALatest IPHYF, TSHA, RLAY, and DNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TSHATaysha Gene Therapies-$0.08-$0.08N/A-$0.08$1.48 million$2.30 million5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million5/5/2025Q1 2025RLAYRelay Therapeutics-$0.50-$0.46+$0.04-$0.46$0.01 million$7.68 million2/26/2025Q4 2024RLAYRelay Therapeutics-$0.57-$0.45+$0.12-$0.45$5.53 millionN/A2/26/2025Q4 2024TSHATaysha Gene Therapies-$0.08-$0.07+$0.01-$0.07$2.05 million$2.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNAGinkgo BioworksN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNAGinkgo BioworksN/A5.795.79IPHYFInnate PharmaN/AN/AN/ARLAYRelay TherapeuticsN/A18.4218.42TSHATaysha Gene Therapies0.485.515.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNAGinkgo Bioworks78.63%IPHYFInnate PharmaN/ARLAYRelay Therapeutics96.98%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipDNAGinkgo Bioworks9.72%IPHYFInnate Pharma31.89%RLAYRelay Therapeutics4.32%TSHATaysha Gene Therapies2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNAGinkgo Bioworks64058.03 million51.89 millionOptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableRLAYRelay Therapeutics330171.45 million160.15 millionOptionableTSHATaysha Gene Therapies180205.06 million199.41 millionOptionableIPHYF, TSHA, RLAY, and DNA HeadlinesRecent News About These CompaniesTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2025 Earnings Call TranscriptMay 16 at 9:32 PM | msn.comTaysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlights: Promising Clinical Progress ...May 16 at 3:43 AM | finance.yahoo.comQ1 2025 Taysha Gene Therapies Inc Earnings CallMay 16 at 3:43 AM | finance.yahoo.comTaysha Gene Therapies Advances in Rett Syndrome TrialsMay 16 at 12:07 AM | tipranks.comTaysha outlines expedited pivotal trial start for TSHA-102 following FDA alignmentMay 15 at 5:40 PM | msn.comTaysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call TranscriptMay 15 at 3:06 PM | seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue EstimatesMay 15 at 10:10 AM | zacks.comTaysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15 at 8:00 AM | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Bought by Octagon Capital Advisors LPMay 15 at 7:39 AM | marketbeat.comGranahan Investment Management LLC Buys 496,482 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 13 at 6:54 AM | marketbeat.comTaysha Gene Therapies (TSHA) to Release Quarterly Earnings on ThursdayMay 13 at 1:29 AM | americanbankingnews.comDAFNA Capital Management LLC Makes New $904,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 10, 2025 | marketbeat.comTaysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15May 8, 2025 | globenewswire.comTaysha Gene Therapies (TSHA) to Release Quarterly Earnings on TuesdayMay 8, 2025 | marketbeat.comMarshall Wace LLP Lowers Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 8, 2025 | marketbeat.comWill Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should KnowMay 6, 2025 | zacks.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 9.3% - What's Next?May 5, 2025 | marketbeat.comAcuta Capital Partners LLC Cuts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 4, 2025 | marketbeat.comWhy Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Up 11.41%May 3, 2025 | aaii.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from AnalystsMay 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPHYF, TSHA, RLAY, and DNA Company DescriptionsGinkgo Bioworks NYSE:DNA$7.92 +0.25 (+3.29%) Closing price 03:59 PM EasternExtended Trading$7.92 0.00 (-0.03%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Innate Pharma OTCMKTS:IPHYF$1.45 0.00 (0.00%) As of 05/15/2025Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Relay Therapeutics NASDAQ:RLAY$2.81 +0.02 (+0.72%) Closing price 04:00 PM EasternExtended Trading$2.82 +0.02 (+0.53%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Taysha Gene Therapies NASDAQ:TSHA$2.70 +0.14 (+5.47%) Closing price 04:00 PM EasternExtended Trading$2.64 -0.07 (-2.41%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
